Aptevo Therapeutics Inc.

APVO Healthcare Biotechnology

Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.62 0.08 −4.71%
Market cap
$3.1M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
4/9
Altman Z
256174.47
Beneish M
3.69
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.08 3.36 3.82 4.03
Net Debt/EBITDA
1.53 2.14 3.65 2.79
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(4.56) (7.51) (16.60) (29.71)
Book value per Share
5.05 10.95 55.09 77.26
Free Cash Flow
(5.45) (7.96) (5.24) (6.69)
Other line items

Show all line items

Columns are period end dates